The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bipolar Disorder Drugs and Treatment Market Research Report 2024
Synopsis
Drug therapy is currently the core method of treating bipolar disorder, that is, the use of emotional stabilizers to adjust the patient's mood. Bipolar disorder is complex and difficult to control. The drug effect of emotional stabilizers can help patients to suppress their emotions when they are too high, to increase their emotions when they are depressed, to stabilize their emotions at a normal level, and to effectively prevent the recurrence of bipolar disorder. The quickest and most effective approach may be convulsive-free electroconvulsive therapy.
Due to the COVID-19 pandemic, the global Bipolar Disorder Drugs and Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Bipolar Disorder Drugs and Treatment market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Bipolar Disorder Drugs and Treatment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Mood Stabilizers accounting for % of the Bipolar Disorder Drugs and Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Bipolar Disorder Drugs and Treatment include AbbVie Inc., Glaxo SmithKline (GSK), Eli Lily and Company, Janssen Pharmaceuticals, Johnson & Johnson, Astellas Pharma Inc, Bristol Myers Squibb, Gedeon Richter PLC. and H. Lundbeck A/S, etc. In terms of revenue, the global 3 largest players have a % market share of Bipolar Disorder Drugs and Treatment in 2021.
This report focuses on Bipolar Disorder Drugs and Treatment volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Bipolar Disorder Drugs and Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Bipolar Disorder Drugs and Treatment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Mood Stabilizers
Anticonvulsants
Antipsychotic Drugs
Antidepressant Drugs
Anti-Anxiety Drugs
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
AbbVie Inc.
Glaxo SmithKline (GSK)
Eli Lily and Company
Janssen Pharmaceuticals
Johnson & Johnson
Astellas Pharma Inc
Bristol Myers Squibb
Gedeon Richter PLC.
H. Lundbeck A/S
Pfizer Inc.
Novartis AG
Otsuka Holdings Co. Ltd
Validus Pharmaceuticals LLC.
Drug therapy is currently the core method of treating bipolar disorder, that is, the use of emotional stabilizers to adjust the patient's mood. Bipolar disorder is complex and difficult to control. The drug effect of emotional stabilizers can help patients to suppress their emotions when they are too high, to increase their emotions when they are depressed, to stabilize their emotions at a normal level, and to effectively prevent the recurrence of bipolar disorder. The quickest and most effective approach may be convulsive-free electroconvulsive therapy.
Due to the COVID-19 pandemic, the global Bipolar Disorder Drugs and Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Bipolar Disorder Drugs and Treatment market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Bipolar Disorder Drugs and Treatment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Mood Stabilizers accounting for % of the Bipolar Disorder Drugs and Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Bipolar Disorder Drugs and Treatment include AbbVie Inc., Glaxo SmithKline (GSK), Eli Lily and Company, Janssen Pharmaceuticals, Johnson & Johnson, Astellas Pharma Inc, Bristol Myers Squibb, Gedeon Richter PLC. and H. Lundbeck A/S, etc. In terms of revenue, the global 3 largest players have a % market share of Bipolar Disorder Drugs and Treatment in 2021.
This report focuses on Bipolar Disorder Drugs and Treatment volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Bipolar Disorder Drugs and Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Bipolar Disorder Drugs and Treatment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Mood Stabilizers
Anticonvulsants
Antipsychotic Drugs
Antidepressant Drugs
Anti-Anxiety Drugs
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
AbbVie Inc.
Glaxo SmithKline (GSK)
Eli Lily and Company
Janssen Pharmaceuticals
Johnson & Johnson
Astellas Pharma Inc
Bristol Myers Squibb
Gedeon Richter PLC.
H. Lundbeck A/S
Pfizer Inc.
Novartis AG
Otsuka Holdings Co. Ltd
Validus Pharmaceuticals LLC.
Index1 Bipolar Disorder Drugs and Treatment Market Overview
1.1 Product Overview and Scope of Bipolar Disorder Drugs and Treatment
1.2 Bipolar Disorder Drugs and Treatment Segment by Type
1.2.1 Global Bipolar Disorder Drugs and Treatment Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Mood Stabilizers
1.2.3 Anticonvulsants
1.2.4 Antipsychotic Drugs
1.2.5 Antidepressant Drugs
1.2.6 Anti-Anxiety Drugs
1.3 Bipolar Disorder Drugs and Treatment Segment by Application
1.3.1 Global Bipolar Disorder Drugs and Treatment Sales Comparison by Application: (2022-2028)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Bipolar Disorder Drugs and Treatment Market Size Estimates and Forecasts
1.4.1 Global Bipolar Disorder Drugs and Treatment Revenue 2017-2028
1.4.2 Global Bipolar Disorder Drugs and Treatment Sales 2017-2028
1.4.3 Bipolar Disorder Drugs and Treatment Market Size by Region: 2017 Versus 2021 Versus 2028
2 Bipolar Disorder Drugs and Treatment Market Competition by Manufacturers
2.1 Global Bipolar Disorder Drugs and Treatment Sales Market Share by Manufacturers (2017-2022)
2.2 Global Bipolar Disorder Drugs and Treatment Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Bipolar Disorder Drugs and Treatment Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Bipolar Disorder Drugs and Treatment Manufacturing Sites, Area Served, Product Type
2.5 Bipolar Disorder Drugs and Treatment Market Competitive Situation and Trends
2.5.1 Bipolar Disorder Drugs and Treatment Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Bipolar Disorder Drugs and Treatment Players Market Share by Revenue
2.5.3 Global Bipolar Disorder Drugs and Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bipolar Disorder Drugs and Treatment Retrospective Market Scenario by Region
3.1 Global Bipolar Disorder Drugs and Treatment Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Bipolar Disorder Drugs and Treatment Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Bipolar Disorder Drugs and Treatment Market Facts & Figures by Country
3.3.1 North America Bipolar Disorder Drugs and Treatment Sales by Country
3.3.2 North America Bipolar Disorder Drugs and Treatment Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Bipolar Disorder Drugs and Treatment Market Facts & Figures by Country
3.4.1 Europe Bipolar Disorder Drugs and Treatment Sales by Country
3.4.2 Europe Bipolar Disorder Drugs and Treatment Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Bipolar Disorder Drugs and Treatment Market Facts & Figures by Region
3.5.1 Asia Pacific Bipolar Disorder Drugs and Treatment Sales by Region
3.5.2 Asia Pacific Bipolar Disorder Drugs and Treatment Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Bipolar Disorder Drugs and Treatment Market Facts & Figures by Country
3.6.1 Latin America Bipolar Disorder Drugs and Treatment Sales by Country
3.6.2 Latin America Bipolar Disorder Drugs and Treatment Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Bipolar Disorder Drugs and Treatment Market Facts & Figures by Country
3.7.1 Middle East and Africa Bipolar Disorder Drugs and Treatment Sales by Country
3.7.2 Middle East and Africa Bipolar Disorder Drugs and Treatment Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Bipolar Disorder Drugs and Treatment Historic Market Analysis by Type
4.1 Global Bipolar Disorder Drugs and Treatment Sales Market Share by Type (2017-2022)
4.2 Global Bipolar Disorder Drugs and Treatment Revenue Market Share by Type (2017-2022)
4.3 Global Bipolar Disorder Drugs and Treatment Price by Type (2017-2022)
5 Global Bipolar Disorder Drugs and Treatment Historic Market Analysis by Application
5.1 Global Bipolar Disorder Drugs and Treatment Sales Market Share by Application (2017-2022)
5.2 Global Bipolar Disorder Drugs and Treatment Revenue Market Share by Application (2017-2022)
5.3 Global Bipolar Disorder Drugs and Treatment Price by Application (2017-2022)
6 Key Companies Profiled
6.1 AbbVie Inc.
6.1.1 AbbVie Inc. Corporation Information
6.1.2 AbbVie Inc. Description and Business Overview
6.1.3 AbbVie Inc. Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.1.4 AbbVie Inc. Bipolar Disorder Drugs and Treatment Product Portfolio
6.1.5 AbbVie Inc. Recent Developments/Updates
6.2 Glaxo SmithKline (GSK)
6.2.1 Glaxo SmithKline (GSK) Corporation Information
6.2.2 Glaxo SmithKline (GSK) Description and Business Overview
6.2.3 Glaxo SmithKline (GSK) Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Glaxo SmithKline (GSK) Bipolar Disorder Drugs and Treatment Product Portfolio
6.2.5 Glaxo SmithKline (GSK) Recent Developments/Updates
6.3 Eli Lily and Company
6.3.1 Eli Lily and Company Corporation Information
6.3.2 Eli Lily and Company Description and Business Overview
6.3.3 Eli Lily and Company Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Eli Lily and Company Bipolar Disorder Drugs and Treatment Product Portfolio
6.3.5 Eli Lily and Company Recent Developments/Updates
6.4 Janssen Pharmaceuticals
6.4.1 Janssen Pharmaceuticals Corporation Information
6.4.2 Janssen Pharmaceuticals Description and Business Overview
6.4.3 Janssen Pharmaceuticals Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Janssen Pharmaceuticals Bipolar Disorder Drugs and Treatment Product Portfolio
6.4.5 Janssen Pharmaceuticals Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Corporation Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Johnson & Johnson Bipolar Disorder Drugs and Treatment Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Astellas Pharma Inc
6.6.1 Astellas Pharma Inc Corporation Information
6.6.2 Astellas Pharma Inc Description and Business Overview
6.6.3 Astellas Pharma Inc Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Astellas Pharma Inc Bipolar Disorder Drugs and Treatment Product Portfolio
6.6.5 Astellas Pharma Inc Recent Developments/Updates
6.7 Bristol Myers Squibb
6.6.1 Bristol Myers Squibb Corporation Information
6.6.2 Bristol Myers Squibb Description and Business Overview
6.6.3 Bristol Myers Squibb Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Bristol Myers Squibb Bipolar Disorder Drugs and Treatment Product Portfolio
6.7.5 Bristol Myers Squibb Recent Developments/Updates
6.8 Gedeon Richter PLC.
6.8.1 Gedeon Richter PLC. Corporation Information
6.8.2 Gedeon Richter PLC. Description and Business Overview
6.8.3 Gedeon Richter PLC. Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Gedeon Richter PLC. Bipolar Disorder Drugs and Treatment Product Portfolio
6.8.5 Gedeon Richter PLC. Recent Developments/Updates
6.9 H. Lundbeck A/S
6.9.1 H. Lundbeck A/S Corporation Information
6.9.2 H. Lundbeck A/S Description and Business Overview
6.9.3 H. Lundbeck A/S Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.9.4 H. Lundbeck A/S Bipolar Disorder Drugs and Treatment Product Portfolio
6.9.5 H. Lundbeck A/S Recent Developments/Updates
6.10 Pfizer Inc.
6.10.1 Pfizer Inc. Corporation Information
6.10.2 Pfizer Inc. Description and Business Overview
6.10.3 Pfizer Inc. Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Pfizer Inc. Bipolar Disorder Drugs and Treatment Product Portfolio
6.10.5 Pfizer Inc. Recent Developments/Updates
6.11 Novartis AG
6.11.1 Novartis AG Corporation Information
6.11.2 Novartis AG Bipolar Disorder Drugs and Treatment Description and Business Overview
6.11.3 Novartis AG Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Novartis AG Bipolar Disorder Drugs and Treatment Product Portfolio
6.11.5 Novartis AG Recent Developments/Updates
6.12 Otsuka Holdings Co. Ltd
6.12.1 Otsuka Holdings Co. Ltd Corporation Information
6.12.2 Otsuka Holdings Co. Ltd Bipolar Disorder Drugs and Treatment Description and Business Overview
6.12.3 Otsuka Holdings Co. Ltd Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Otsuka Holdings Co. Ltd Bipolar Disorder Drugs and Treatment Product Portfolio
6.12.5 Otsuka Holdings Co. Ltd Recent Developments/Updates
6.13 Validus Pharmaceuticals LLC.
6.13.1 Validus Pharmaceuticals LLC. Corporation Information
6.13.2 Validus Pharmaceuticals LLC. Bipolar Disorder Drugs and Treatment Description and Business Overview
6.13.3 Validus Pharmaceuticals LLC. Bipolar Disorder Drugs and Treatment Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Validus Pharmaceuticals LLC. Bipolar Disorder Drugs and Treatment Product Portfolio
6.13.5 Validus Pharmaceuticals LLC. Recent Developments/Updates
7 Bipolar Disorder Drugs and Treatment Manufacturing Cost Analysis
7.1 Bipolar Disorder Drugs and Treatment Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Bipolar Disorder Drugs and Treatment
7.4 Bipolar Disorder Drugs and Treatment Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Bipolar Disorder Drugs and Treatment Distributors List
8.3 Bipolar Disorder Drugs and Treatment Customers
9 Bipolar Disorder Drugs and Treatment Market Dynamics
9.1 Bipolar Disorder Drugs and Treatment Industry Trends
9.2 Bipolar Disorder Drugs and Treatment Market Drivers
9.3 Bipolar Disorder Drugs and Treatment Market Challenges
9.4 Bipolar Disorder Drugs and Treatment Market Restraints
10 Global Market Forecast
10.1 Bipolar Disorder Drugs and Treatment Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Bipolar Disorder Drugs and Treatment by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Bipolar Disorder Drugs and Treatment by Type (2023-2028)
10.2 Bipolar Disorder Drugs and Treatment Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Bipolar Disorder Drugs and Treatment by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Bipolar Disorder Drugs and Treatment by Application (2023-2028)
10.3 Bipolar Disorder Drugs and Treatment Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Bipolar Disorder Drugs and Treatment by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Bipolar Disorder Drugs and Treatment by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesList of Tables
Table 1. Global Bipolar Disorder Drugs and Treatment Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Bipolar Disorder Drugs and Treatment Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Bipolar Disorder Drugs and Treatment Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Bipolar Disorder Drugs and Treatment Market Competitive Situation by Manufacturers in 2021
Table 5. Global Bipolar Disorder Drugs and Treatment Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Bipolar Disorder Drugs and Treatment Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Bipolar Disorder Drugs and Treatment Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Bipolar Disorder Drugs and Treatment Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Bipolar Disorder Drugs and Treatment Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Bipolar Disorder Drugs and Treatment Manufacturing Sites and Area Served
Table 11. Manufacturers Bipolar Disorder Drugs and Treatment Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Bipolar Disorder Drugs and Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bipolar Disorder Drugs and Treatment as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Bipolar Disorder Drugs and Treatment Sales by Region (2017-2022) & (K Units)
Table 16. Global Bipolar Disorder Drugs and Treatment Sales Market Share by Region (2017-2022)
Table 17. Global Bipolar Disorder Drugs and Treatment Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Bipolar Disorder Drugs and Treatment Revenue Market Share by Region (2017-2022)
Table 19. North America Bipolar Disorder Drugs and Treatment Sales by Country (2017-2022) & (K Units)
Table 20. North America Bipolar Disorder Drugs and Treatment Sales Market Share by Country (2017-2022)
Table 21. North America Bipolar Disorder Drugs and Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Bipolar Disorder Drugs and Treatment Revenue Market Share by Country (2017-2022)
Table 23. Europe Bipolar Disorder Drugs and Treatment Sales by Country (2017-2022) & (K Units)
Table 24. Europe Bipolar Disorder Drugs and Treatment Sales Market Share by Country (2017-2022)
Table 25. Europe Bipolar Disorder Drugs and Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Bipolar Disorder Drugs and Treatment Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Bipolar Disorder Drugs and Treatment Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Bipolar Disorder Drugs and Treatment Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Bipolar Disorder Drugs and Treatment Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Bipolar Disorder Drugs and Treatment Revenue Market Share by Region (2017-2022)
Table 31. Latin America Bipolar Disorder Drugs and Treatment Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Bipolar Disorder Drugs and Treatment Sales Market Share by Country (2017-2022)
Table 33. Latin America Bipolar Disorder Drugs and Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Bipolar Disorder Drugs and Treatment Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Bipolar Disorder Drugs and Treatment Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Bipolar Disorder Drugs and Treatment Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Bipolar Disorder Drugs and Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Bipolar Disorder Drugs and Treatment Revenue Market Share by Country (2017-2022)
Table 39. Global Bipolar Disorder Drugs and Treatment Sales by Type (2017-2022) & (K Units)
Table 40. Global Bipolar Disorder Drugs and Treatment Sales Market Share by Type (2017-2022)
Table 41. Global Bipolar Disorder Drugs and Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Bipolar Disorder Drugs and Treatment Revenue Share by Type (2017-2022)
Table 43. Global Bipolar Disorder Drugs and Treatment Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Bipolar Disorder Drugs and Treatment Sales (K Units) by Application (2017-2022)
Table 45. Global Bipolar Disorder Drugs and Treatment Sales Market Share by Application (2017-2022)
Table 46. Global Bipolar Disorder Drugs and Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Bipolar Disorder Drugs and Treatment Revenue Share by Application (2017-2022)
Table 48. Global Bipolar Disorder Drugs and Treatment Price by Application (2017-2022) & (US$/Unit)
Table 49. AbbVie Inc. Corporation Information
Table 50. AbbVie Inc. Description and Business Overview
Table 51. AbbVie Inc. Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. AbbVie Inc. Bipolar Disorder Drugs and Treatment Product
Table 53. AbbVie Inc. Recent Developments/Updates
Table 54. Glaxo SmithKline (GSK) Corporation Information
Table 55. Glaxo SmithKline (GSK) Description and Business Overview
Table 56. Glaxo SmithKline (GSK) Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. Glaxo SmithKline (GSK) Bipolar Disorder Drugs and Treatment Product
Table 58. Glaxo SmithKline (GSK) Recent Developments/Updates
Table 59. Eli Lily and Company Corporation Information
Table 60. Eli Lily and Company Description and Business Overview
Table 61. Eli Lily and Company Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Eli Lily and Company Bipolar Disorder Drugs and Treatment Product
Table 63. Eli Lily and Company Recent Developments/Updates
Table 64. Janssen Pharmaceuticals Corporation Information
Table 65. Janssen Pharmaceuticals Description and Business Overview
Table 66. Janssen Pharmaceuticals Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. Janssen Pharmaceuticals Bipolar Disorder Drugs and Treatment Product
Table 68. Janssen Pharmaceuticals Recent Developments/Updates
Table 69. Johnson & Johnson Corporation Information
Table 70. Johnson & Johnson Description and Business Overview
Table 71. Johnson & Johnson Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Johnson & Johnson Bipolar Disorder Drugs and Treatment Product
Table 73. Johnson & Johnson Recent Developments/Updates
Table 74. Astellas Pharma Inc Corporation Information
Table 75. Astellas Pharma Inc Description and Business Overview
Table 76. Astellas Pharma Inc Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Astellas Pharma Inc Bipolar Disorder Drugs and Treatment Product
Table 78. Astellas Pharma Inc Recent Developments/Updates
Table 79. Bristol Myers Squibb Corporation Information
Table 80. Bristol Myers Squibb Description and Business Overview
Table 81. Bristol Myers Squibb Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Bristol Myers Squibb Bipolar Disorder Drugs and Treatment Product
Table 83. Bristol Myers Squibb Recent Developments/Updates
Table 84. Gedeon Richter PLC. Corporation Information
Table 85. Gedeon Richter PLC. Description and Business Overview
Table 86. Gedeon Richter PLC. Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. Gedeon Richter PLC. Bipolar Disorder Drugs and Treatment Product
Table 88. Gedeon Richter PLC. Recent Developments/Updates
Table 89. H. Lundbeck A/S Corporation Information
Table 90. H. Lundbeck A/S Description and Business Overview
Table 91. H. Lundbeck A/S Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. H. Lundbeck A/S Bipolar Disorder Drugs and Treatment Product
Table 93. H. Lundbeck A/S Recent Developments/Updates
Table 94. Pfizer Inc. Corporation Information
Table 95. Pfizer Inc. Description and Business Overview
Table 96. Pfizer Inc. Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Pfizer Inc. Bipolar Disorder Drugs and Treatment Product
Table 98. Pfizer Inc. Recent Developments/Updates
Table 99. Novartis AG Corporation Information
Table 100. Novartis AG Description and Business Overview
Table 101. Novartis AG Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 102. Novartis AG Bipolar Disorder Drugs and Treatment Product
Table 103. Novartis AG Recent Developments/Updates
Table 104. Otsuka Holdings Co. Ltd Corporation Information
Table 105. Otsuka Holdings Co. Ltd Description and Business Overview
Table 106. Otsuka Holdings Co. Ltd Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 107. Otsuka Holdings Co. Ltd Bipolar Disorder Drugs and Treatment Product
Table 108. Otsuka Holdings Co. Ltd Recent Developments/Updates
Table 109. Validus Pharmaceuticals LLC. Corporation Information
Table 110. Validus Pharmaceuticals LLC. Description and Business Overview
Table 111. Validus Pharmaceuticals LLC. Bipolar Disorder Drugs and Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 112. Validus Pharmaceuticals LLC. Bipolar Disorder Drugs and Treatment Product
Table 113. Validus Pharmaceuticals LLC. Recent Developments/Updates
Table 114. Production Base and Market Concentration Rate of Raw Material
Table 115. Key Suppliers of Raw Materials
Table 116. Bipolar Disorder Drugs and Treatment Distributors List
Table 117. Bipolar Disorder Drugs and Treatment Customers List
Table 118. Bipolar Disorder Drugs and Treatment Market Trends
Table 119. Bipolar Disorder Drugs and Treatment Market Drivers
Table 120. Bipolar Disorder Drugs and Treatment Market Challenges
Table 121. Bipolar Disorder Drugs and Treatment Market Restraints
Table 122. Global Bipolar Disorder Drugs and Treatment Sales Forecast by Type (2023-2028) & (K Units)
Table 123. Global Bipolar Disorder Drugs and Treatment Sales Market Share Forecast by Type (2023-2028)
Table 124. Global Bipolar Disorder Drugs and Treatment Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 125. Global Bipolar Disorder Drugs and Treatment Revenue Market Share Forecast by Type (2023-2028)
Table 126. Global Bipolar Disorder Drugs and Treatment Sales Forecast by Application (2023-2028) & (K Units)
Table 127. Global Bipolar Disorder Drugs and Treatment Sales Market Share Forecast by Application (2023-2028)
Table 128. Global Bipolar Disorder Drugs and Treatment Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 129. Global Bipolar Disorder Drugs and Treatment Revenue Market Share Forecast by Application (2023-2028)
Table 130. Global Bipolar Disorder Drugs and Treatment Sales Forecast by Region (2023-2028) & (K Units)
Table 131. Global Bipolar Disorder Drugs and Treatment Sales Market Share Forecast by Region (2023-2028)
Table 132. Global Bipolar Disorder Drugs and Treatment Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 133. Global Bipolar Disorder Drugs and Treatment Revenue Market Share Forecast by Region (2023-2028)
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Bipolar Disorder Drugs and Treatment
Figure 2. Global Bipolar Disorder Drugs and Treatment Market Share by Type in 2021 & 2028
Figure 3. Mood Stabilizers Product Picture
Figure 4. Anticonvulsants Product Picture
Figure 5. Antipsychotic Drugs Product Picture
Figure 6. Antidepressant Drugs Product Picture
Figure 7. Anti-Anxiety Drugs Product Picture
Figure 8. Global Bipolar Disorder Drugs and Treatment Market Share by Application in 2021 & 2028
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Global Bipolar Disorder Drugs and Treatment Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Bipolar Disorder Drugs and Treatment Market Size (2017-2028) & (US$ Million)
Figure 13. Global Bipolar Disorder Drugs and Treatment Sales (2017-2028) & (K Units)
Figure 14. Bipolar Disorder Drugs and Treatment Sales Share by Manufacturers in 2021
Figure 15. Global Bipolar Disorder Drugs and Treatment Revenue Share by Manufacturers in 2021
Figure 16. The Global 5 and 10 Largest Bipolar Disorder Drugs and Treatment Players: Market Share by Revenue in 2021
Figure 17. Bipolar Disorder Drugs and Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 18. Global Bipolar Disorder Drugs and Treatment Sales Market Share by Region (2017-2022)
Figure 19. Global Bipolar Disorder Drugs and Treatment Sales Market Share by Region in 2021
Figure 20. Global Bipolar Disorder Drugs and Treatment Revenue Market Share by Region (2017-2022)
Figure 21. Global Bipolar Disorder Drugs and Treatment Revenue Market Share by Region in 2021
Figure 22. United States Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Canada Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Germany Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. France Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. U.K. Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Italy Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Russia Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. China Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Japan Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. South Korea Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. India Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Australia Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. China Taiwan Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Indonesia Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Thailand Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Malaysia Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Mexico Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Brazil Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Argentina Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Turkey Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Saudi Arabia Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. UAE Bipolar Disorder Drugs and Treatment Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Sales Market Share of Bipolar Disorder Drugs and Treatment by Type (2017-2022)
Figure 45. Manufacturing Cost Structure of Bipolar Disorder Drugs and Treatment
Figure 46. Manufacturing Process Analysis of Bipolar Disorder Drugs and Treatment
Figure 47. Bipolar Disorder Drugs and Treatment Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
